PE20110283A1 - Composicion que contiene nifurtimox - Google Patents
Composicion que contiene nifurtimoxInfo
- Publication number
- PE20110283A1 PE20110283A1 PE2010001201A PE2010001201A PE20110283A1 PE 20110283 A1 PE20110283 A1 PE 20110283A1 PE 2010001201 A PE2010001201 A PE 2010001201A PE 2010001201 A PE2010001201 A PE 2010001201A PE 20110283 A1 PE20110283 A1 PE 20110283A1
- Authority
- PE
- Peru
- Prior art keywords
- composition containing
- nifurtimox
- composition
- containing nifurtimox
- cyclooctadepsipeptides
- Prior art date
Links
- ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 title abstract 2
- 229960002644 nifurtimox Drugs 0.000 title abstract 2
- MOOFYEJFXBSZGE-LQGKIZFRSA-N 1,2-bis[(e)-(4-chlorophenyl)methylideneamino]guanidine Chemical compound C=1C=C(Cl)C=CC=1\C=N\N=C(/N)N\N=C\C1=CC=C(Cl)C=C1 MOOFYEJFXBSZGE-LQGKIZFRSA-N 0.000 abstract 1
- 239000000921 anthelmintic agent Substances 0.000 abstract 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 abstract 1
- 229960002227 clindamycin Drugs 0.000 abstract 1
- 230000036576 dermal application Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical compound C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 abstract 1
- 229960001575 emodepside Drugs 0.000 abstract 1
- 108010056417 emodepside Proteins 0.000 abstract 1
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 abstract 1
- 229960000611 pyrimethamine Drugs 0.000 abstract 1
- 229960004591 robenidine Drugs 0.000 abstract 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004306 sulfadiazine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Catching Or Destruction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008031284A DE102008031284A1 (de) | 2008-07-02 | 2008-07-02 | Neue Bekämpfungsmöglichkeit der Giardiose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110283A1 true PE20110283A1 (es) | 2011-05-07 |
Family
ID=41077987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010001201A PE20110283A1 (es) | 2008-07-02 | 2009-06-20 | Composicion que contiene nifurtimox |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8440612B2 (de) |
| EP (1) | EP2310018B1 (de) |
| JP (1) | JP5627579B2 (de) |
| KR (1) | KR101720805B1 (de) |
| CN (1) | CN102083441B (de) |
| AR (1) | AR072425A1 (de) |
| AU (1) | AU2009266125B2 (de) |
| BR (1) | BRPI0913889B1 (de) |
| CA (1) | CA2729730C (de) |
| CL (2) | CL2010001577A1 (de) |
| CO (1) | CO6321270A2 (de) |
| CR (1) | CR20110022A (de) |
| DE (1) | DE102008031284A1 (de) |
| DK (1) | DK2310018T3 (de) |
| DO (1) | DOP2010000405A (de) |
| EC (1) | ECSP10010720A (de) |
| ES (1) | ES2444581T3 (de) |
| HK (1) | HK1158113A1 (de) |
| IL (1) | IL209698A (de) |
| MX (1) | MX2010014446A (de) |
| MY (1) | MY157007A (de) |
| NI (1) | NI201100008A (de) |
| NZ (1) | NZ590276A (de) |
| PE (1) | PE20110283A1 (de) |
| PL (1) | PL2310018T3 (de) |
| RU (1) | RU2538713C9 (de) |
| SV (1) | SV2011003785A (de) |
| UA (1) | UA103328C2 (de) |
| WO (1) | WO2010000399A1 (de) |
| ZA (1) | ZA201009225B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9173898B2 (en) * | 2010-10-12 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating giardiasis |
| RS62130B1 (sr) | 2015-05-20 | 2021-08-31 | Boehringer Ingelheim Animal Health Usa Inc | Antihelmintička depsipeptidna jedinjenja |
| KR102427124B1 (ko) | 2015-12-28 | 2022-07-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 뎁시펩티드 화합물 |
| AU2017361099A1 (en) | 2016-11-16 | 2019-06-06 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic depsipeptide compounds |
| EP3750527A1 (de) * | 2019-06-13 | 2020-12-16 | Bayer AG | Stabile tablettenformulierung von nifurtimox und verfahren zur herstellung davon |
| CN114377018B (zh) * | 2020-10-21 | 2024-02-06 | 中国医学科学院药物研究所 | 硝呋莫司在制备抗流感病毒药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1170957B (de) * | 1962-11-23 | 1964-05-27 | Bayer Ag | Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten |
| JPH081908B2 (ja) * | 1987-07-22 | 1996-01-10 | 三菱電機株式会社 | 超格子半導体素子 |
| NO176766C (no) | 1989-02-07 | 1995-05-24 | Meiji Seika Kaisha | Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet |
| WO1993019053A1 (fr) | 1992-03-17 | 1993-09-30 | Fujisawa Pharmaceutical Co., Ltd. | Derive de depsipeptide, production et utilisation |
| DE4317458A1 (de) | 1992-06-11 | 1993-12-16 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung |
| CN1073560C (zh) | 1993-02-19 | 2001-10-24 | 明治制果株式会社 | 环缩酚酸肽pf1022衍生物 |
| DE4317432A1 (de) | 1993-05-26 | 1994-12-01 | Bayer Ag | Octacyclodepsipeptide mit endoparasitizider Wirkung |
| DE4317457A1 (de) | 1993-05-26 | 1994-12-01 | Bayer Ag | Octacyclodepsipeptide mit endoparasitizider Wirkung |
| JP3263947B2 (ja) | 1993-09-06 | 2002-03-11 | 藤沢薬品工業株式会社 | 環状デプシペプチド化合物 |
| DE4401389A1 (de) | 1994-01-19 | 1995-07-20 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung |
| DE4406025A1 (de) | 1994-02-24 | 1995-08-31 | Bayer Ag | Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung |
| RU2074038C1 (ru) * | 1994-06-16 | 1997-02-27 | Товарищество с ограниченной ответственностью Предприятие "ТЕПАРК" | Способ изготовления полых металлических емкостей |
| DE4437198A1 (de) | 1994-10-18 | 1996-04-25 | Bayer Ag | Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden |
| ES2322678T3 (es) | 1995-06-30 | 2009-06-24 | Astellas Pharma Inc. | Derivado de depsipeptido, procedimiento para su produccion y nuevo intermedio del mismo. |
| PL186168B1 (pl) | 1995-09-22 | 2003-11-28 | Bayer Ag | Nowe pochodne cyklodepsipeptydowej substancji PF1022 i kompozycje przeciwrobacze je zawierające |
| DE19545639A1 (de) | 1995-12-07 | 1997-06-12 | Bayer Ag | Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen |
| US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
| US5874630A (en) * | 1998-01-06 | 1999-02-23 | Occidental Chemical Corporation | Synthesis of mercaptans from alcohols |
| US6133228A (en) * | 1998-05-28 | 2000-10-17 | Firmenich Sa | Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters |
| DE19828047A1 (de) * | 1998-06-24 | 1999-12-30 | Bayer Ag | Substituierte Cyclooctadepsipeptide |
| MX2007005570A (es) * | 2004-11-12 | 2007-07-09 | Celgene Corp | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. |
| DE102005033496A1 (de) | 2005-07-19 | 2007-01-25 | Bayer Healthcare Ag | Desinfektionsmittel |
-
2008
- 2008-07-02 DE DE102008031284A patent/DE102008031284A1/de not_active Withdrawn
-
2009
- 2009-06-20 CN CN2009801255081A patent/CN102083441B/zh not_active Expired - Fee Related
- 2009-06-20 RU RU2011103475/15A patent/RU2538713C9/ru not_active IP Right Cessation
- 2009-06-20 PE PE2010001201A patent/PE20110283A1/es not_active Application Discontinuation
- 2009-06-20 NZ NZ590276A patent/NZ590276A/xx not_active IP Right Cessation
- 2009-06-20 BR BRPI0913889A patent/BRPI0913889B1/pt not_active IP Right Cessation
- 2009-06-20 MX MX2010014446A patent/MX2010014446A/es active IP Right Grant
- 2009-06-20 JP JP2011515179A patent/JP5627579B2/ja not_active Expired - Fee Related
- 2009-06-20 US US13/000,715 patent/US8440612B2/en not_active Expired - Fee Related
- 2009-06-20 DK DK09772099.9T patent/DK2310018T3/da active
- 2009-06-20 ES ES09772099.9T patent/ES2444581T3/es active Active
- 2009-06-20 MY MYPI2010006319A patent/MY157007A/en unknown
- 2009-06-20 CA CA2729730A patent/CA2729730C/en not_active Expired - Fee Related
- 2009-06-20 PL PL09772099T patent/PL2310018T3/pl unknown
- 2009-06-20 AU AU2009266125A patent/AU2009266125B2/en not_active Ceased
- 2009-06-20 KR KR1020117002111A patent/KR101720805B1/ko not_active Expired - Fee Related
- 2009-06-20 EP EP09772099.9A patent/EP2310018B1/de not_active Not-in-force
- 2009-06-20 WO PCT/EP2009/004475 patent/WO2010000399A1/de active Application Filing
- 2009-06-20 UA UAA201101135A patent/UA103328C2/uk unknown
- 2009-06-30 AR ARP090102439A patent/AR072425A1/es not_active Application Discontinuation
-
2010
- 2010-12-01 IL IL209698A patent/IL209698A/en active IP Right Grant
- 2010-12-22 ZA ZA2010/09225A patent/ZA201009225B/en unknown
- 2010-12-27 DO DO2010000405A patent/DOP2010000405A/es unknown
- 2010-12-27 CO CO10162857A patent/CO6321270A2/es active IP Right Grant
- 2010-12-27 EC EC2010010720A patent/ECSP10010720A/es unknown
- 2010-12-27 CL CL2010001577A patent/CL2010001577A1/es unknown
-
2011
- 2011-01-03 SV SV2011003785A patent/SV2011003785A/es active IP Right Grant
- 2011-01-05 NI NI201100008A patent/NI201100008A/es unknown
- 2011-01-11 CR CR20110022A patent/CR20110022A/es unknown
- 2011-11-25 HK HK11112838.8A patent/HK1158113A1/xx not_active IP Right Cessation
-
2013
- 2013-03-15 CL CL2013000709A patent/CL2013000709A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110283A1 (es) | Composicion que contiene nifurtimox | |
| CR10748A (es) | Compuesto de indol | |
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| CL2008000899A1 (es) | Compuestos derivados de 3-imidazolil-indolilo, inhibidores de la interaccion entre p53 y mdm2 y/o mdm4; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades proliferativas. | |
| BRPI1015229A2 (pt) | Seringa pré-abastecida ou auto-injetor. | |
| CL2008001612A1 (es) | 5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion. | |
| MX350541B (es) | Materiales y metodos para mejorar la funcion gastrointestinal. | |
| CL2015001792A1 (es) | Una composicion que comprende (i) un complejo de haluro de (aminoacido o trialquil glicina) y zinc y (ii) cisteina, util para la eliminacion de las bacterias, la reduccion de la transpiracion y/o la reduccion del olor corporal, o para el cuidado oral, entre otras. | |
| CO6680667A2 (es) | Derivados ester de ácido borónico cíclico y sus usos terapéuticos | |
| AR093386A1 (es) | Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento | |
| EA201170876A1 (ru) | Применение способной к вспениванию композиции, по существу, не содержащей фармацевтически активные ингредиенты, для лечения кожи человека | |
| CL2008001197A1 (es) | Compuestos derivados de amidas sustituidas, moduladoras de la actividad de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome metabolico, resistencia a la insulina, dislipidemia, entre otras. | |
| CR20150174A (es) | Composición esterilizada que comprende al menos un ácido hialuronico y ascorbil fosfato de magnesio | |
| CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
| PE20121709A1 (es) | Una composicion farmaceutica para tratar cancer que comprende tripsinogeno y/o quimotripsinogeno y un agente activo seleccionado a partir de un compuesto de selenio, un compuesto vainilloide y un agente reductor de glicolisis citoplasmica | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| CO6410278A2 (es) | Disoluciones pediátricas que continen un beta-bloqueante | |
| CL2011002182A1 (es) | Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades.. | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| PE20190210A1 (es) | Aplicaciones de carrimicina en la infeccion por micobacterium tuberculosis resistente | |
| CL2012003266A1 (es) | Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana. | |
| PE20121538A1 (es) | Combinaciones terapeuticas de teobromina y una antihistamina | |
| PE20110370A1 (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
| CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |